首页> 外文期刊>BMC Veterinary Research >Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)
【24h】

Treatment of canine atopic dermatitis: 2015 updated guidelines from the International Committee on Allergic Diseases of Animals (ICADA)

机译:犬特应性皮炎的治疗:国际动物过敏性疾病委员会(ICADA)的2015年更新指南

获取原文
获取外文期刊封面目录资料

摘要

Background In 2010, the International Task Force on Canine Atopic Dermatitis (now International Committee on Allergic Diseases of Animals, ICADA) published the first consensus guidelines for the treatment of atopic dermatitis (AD) in dogs. This is the first 5-year minor update of this document. Results The treatment of acute flares of AD should involve the search for, and then elimination of, the cause of the flares, bathing with mild shampoos, and controlling pruritus and skin lesions with interventions that include topical and/or oral glucocorticoids or oclacitinib. For chronic canine AD, the first steps in management are the identification and avoidance of flare factors, as well as ensuring that there is adequate skin and coat hygiene and care; this might include more frequent bathing and possibly increasing essential fatty acid intake. The medications currently most effective in reducing chronic pruritus and skin lesions are topical and oral glucocorticoids, oral ciclosporin, oral oclacitinib, and, where available, injectable recombinant interferons. Allergen-specific immunotherapy and proactive intermittent topical glucocorticoid applications are the only interventions likely to prevent or delay the recurrence of flares of AD. Conclusions This first 5-year minor update of the international consensus guidelines for treatment of AD in dogs further establishes that the treatment of this disease is multifaceted, and that interventions should be combined for a proven (or likely) optimal benefit. Importantly, treatment plans are likely to vary between dogs and, for the same dog, between times when the disease is at different stages.
机译:背景技术2010年,犬特应性皮炎国际工作组(现为国际动物过敏性疾病委员会,ICADA)发布了第一个治疗犬特应性皮炎(AD)的共识性指南。这是本文档的第一个5年次更新。结果AD的急性耀斑的治疗应​​包括寻找并消除引起耀斑的原因,用中性洗发剂沐浴,并通过局部和/或口服糖皮质激素或oclacitinib干预来控制瘙痒和皮肤损伤。对于慢性犬AD,管理的第一步是识别和避免耀斑因素,并确保有足够的皮肤和外套卫生和护理;这可能包括更频繁地洗澡和可能增加必需脂肪酸的摄入量。当前最有效的减轻慢性瘙痒和皮肤损伤的药物是局部和口服糖皮质激素,口服环孢素,口服奥卡替尼,以及在可获得的情况下注射重组干扰素。过敏原特异性免疫疗法和主动间歇性局部糖皮质激素应用是可能预防或延迟AD发作的唯一干预措施。结论国际上关于狗AD治疗指南的第一个5年次小更新,进一步确定了该疾病的治疗是多方面的,并且应结合干预措施以证明(或可能的)最佳益处。重要的是,治疗方案可能在狗之间,对于同一只狗,在疾病处于不同阶段的时间之间可能会有所不同。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号